Navigation Links
Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order
Date:11/20/2007

GARDNER, Mass., Nov. 20 /PRNewswire-FirstCall/ -- Precision Optics Corporation, Inc. (OTC Bulletin Board: POCI), (the "Company") today announced operating results on an unaudited basis for the first quarter of fiscal year 2008 ended September 30, 2007.

First Quarter Operating Results

Revenues -- Total revenues for the quarter ended September 30, 2007 were $1,101,728, an increase of $674,103 or 158% from the same period in the prior year. This represents the second highest quarterly revenue in six years. The increase was due principally to shipments to a significant new customer of an advanced surgical visualization system, along with the introduction of other new products. The advanced surgical visualization system relied heavily on the Company's experience and superior technology in the area of medical optics systems, specifically in the area of advanced optical endoscopic instrumentation.

Net Loss -- For the quarter ended September 30, 2007, net loss was $466,848, or $0.02 per share, a decrease of $221,331 from the net loss of $688,179 or $0.04 per share, for the same period last year. The decrease in net loss is the result of higher sales volumes along with a corresponding increase in gross profit. Gross profit for the quarter ended September 30, 2007, as a percentage of revenues, increased from 10% for the quarter ended September 30, 2006 to 28%. The weighted average common shares outstanding for the quarters ended September 30, 2007 and 2006 were 25,458,212 and 15,458,212, respectively.

Cash Flow and Expenditures -- For the quarter ended September 30, 2007, cash and cash equivalents decreased by $300,450 compared to a decrease of $755,449 for the same period last year. The improved decrease in cash and cash equivalents for the quarter ended September 30, 2007 was due primarily from less cash being used in operating activities, mostly due to higher sales volumes along with an increase in gross profit, compared to the same period la
'/>"/>

SOURCE Precision Optics Corporation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years
2. Varian Medical Systems to Unveil RapidArc(TM) Volumetric Arc Therapy and Other Products Designed to Speed Delivery of Precision Radiotherapy and Brachytherapy
3. New Generation Xcelodose(R)S Precision Drug Powder Micro-filling System Offers 50% Increased Throughput
4. AZoOptics.com - The A to Z of Optics Launched By AZoNetwork
5. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
6. Brooke Franchise Corporation Announces Selected July Results
7. MedThink Communications Retained by NanoBio Corporation
8. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
9. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
10. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
11. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... A Florida State University College of Medicine re... important new layer of regulation in the cell div...anding of the way cancer begins. , Wang, an assi...ege of Medicine, said the findings will lead to an...d to the design of new drugs that kill cancer cell...
(Date:11/21/2008)...PRNewswire-FirstCall/ -- The Providence Service,C...Craig A. Norris, the Company,s,Chief Operating Of...f,Directors. Mr. Norris, appointment fills the v...en I. Geringer and returns the board to six member... the Board. , Mr. Norris, age 41, has been ...
(Date:11/21/2008)...ad to a novel technique to combat cancer, study sa...ws) -- Belgian researchers have discovered that so...or food, and this might lead to new treatments tha... proliferate, all cells in the body need to produc... a process that requires oxygen. Compared with nor...
(Date:11/21/2008)...d To Vigorously Protect Investment And Restore Sha...ewswire-USNewswire/ -- Dr. Stephen Joffe, Craig Jo...heir Schedule 13D with the U.S. Securities and Exc...D disclosing ownership of 11.4% of LCA-Vision, Inc...ixed-site laser vision correction centers in 33 st...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7
...ith wins a court battle against United Health Euro...lthcare company and spoils their plan to run a GP ...for the tender to provide family doctors for the p...tinghamshire border. The North Eastern Derbyshire...
...abies being treated at the Royal Blackburn Hospita...n their skin, during routine tests.// Since then ...me the babies were being treated in the neonatal i...officials have said that none of these children be...
...r sudden infant death syndrome has been the cause ...to ensure the baby sleeps on its back. In a bid to... infant vulnerable, researchers discovered that in...ngs related genes were prone to the risk of SIDS. ...
...ed nuclear scientist Abdul Qader Khan, diagnosed w...nd the public would be kept informed of his health... health condition of Khan is of public interest, t...t best medical care was being provided to Khan in ...
Other Medicine News:Health News:Pensioner wins over a US healthcare giant 2Health News:Pakistan Assures of Providing Best Medical Care to Abdul Qader Khan 2
(Date:11/20/2008)... Calif., Nov. 20 Milk. It does a b...originally thought. After years of,research, scie...es found in,cow,s milk that stimulate the body,s ...ew the Multimedia News Release, go to:, http://www... While developing new cancer therapies, the chie...
(Date:11/20/2008)...Nov. 20 Clinical data from a prosp...nnual Veith Symposium shows DVT,treatment with th...us,Vascular, Inc. (Santa Clara, CA) successfully ...t 20 minutes. , This technique, called isol...ood flow more quickly and safely than current cath...
(Date:11/19/2008)...AKS, Calif., Nov. 19 Amg...ncology Company, a subsidiary of,Takeda Pharmaceu... that,enrollment in the Phase 3 MONET1 trial eval...clitaxel and carboplatin for the first-line treatm...) has been temporarily suspended,following a plan...
(Date:11/19/2008)...l., Nov. 19 Isogen, a contract dev...le filling, today announced the first,phase launc... founded to,specifically address the process, fac...ith the $2 billion highly-niched, low-volume clini...rket segment. , Companies can invest over $...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Isogen Launches Major New Facility to Address Global Biopharma Demand 2New Program Website Targets Jewish Children Teens and Adults Suffering from the Impact of Childhood Maltreatment 20926 1New Program Website Targets Jewish Children Teens and Adults Suffering from the Impact of Childhood Maltreatment 20926 2Ferndale and Foamix Execute License Agreement for Development of Non Steroidal Foam for Atopic Dermatitis 5760 1Ferndale and Foamix Execute License Agreement for Development of Non Steroidal Foam for Atopic Dermatitis 5760 2Chronic Stomach Inflammation Boosts Cancer Risk 20924 1Chronic Stomach Inflammation Boosts Cancer Risk 20924 2Canine Cancer Web Exclusive for Dog Owners and Lovers Presented by Morris Animal Foundation Features Colorado State and Cornell University Veterina 20919 1Canine Cancer Web Exclusive for Dog Owners and Lovers Presented by Morris Animal Foundation Features Colorado State and Cornell University Veterina 20919 2
...ieves All Key Endpoints for Both Efficacy and Safe...rstCall/ --,Indevus Pharmaceuticals, Inc. today an...inetic trial for NEBIDO (testosterone,undecanoate)...nder,development for the treatment of male hypogon...ng Pharma AG, Germany. The data,from the recently ...
... is evaluating zonisamide SR as a novel component ... June 07, 2007 /PRNewswire-FirstCall/ -- Orexigen(...ny focused on the,treatment of central nervous sys...day announced results from a Phase I trial evaluat...rietary,sustained-release (SR) formulation of zon...
Other Medicine Technology:Indevus Reports Positive Data From Phase III NEBIDO Trial 2Indevus Reports Positive Data From Phase III NEBIDO Trial 3Indevus Reports Positive Data From Phase III NEBIDO Trial 4Indevus Reports Positive Data From Phase III NEBIDO Trial 5Indevus Reports Positive Data From Phase III NEBIDO Trial 6OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry.
BD Vacutainer® Specialty Tubes - Sedimentation Rate Determination (SRD)
Inquire
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
Medicine Products: